Product logins

Find logins to all Clarivate products below.


ENT Devices | Market Insights | Asia Pacific | 2022

The COVID-19 pandemic will have a significant impact on ENT procedure volumes as growing developments in alternative treatment such as antibiotics and the continued effort of various associations to promote alternatives to surgery will affect the rebound of procedures. However, as the situation around COVID-19 stabilizes, there will be increasing adoption of innovative and premium-priced products, such as flexiblescopes, RF handpieces, and powered instruments. As a result, the Asia Pacific market for ENT devices will grow at a relatively modest pace following the impact of the pandemic.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for ENT devices in the Asia Pacific region across a 11-year period.

Related Medtech Insights Reports

Report
Cardiac Rhythm Management Devices – Market Insights – Asia Pacific
The Asia Pacific CRM device market will register modest growth over the forecast period. Key growth drivers include the rising adoption of premium-priced technologies such as CRT devices, leadless…
Report
Aortic Repair Devices – Market Insights – Asia Pacific
The Asia Pacific aortic repair device market is projected to experience robust growth during the forecast period, fueled by rising endovascular procedure volumes, ongoing innovation in aortic stent…
Report
Cardiac Rhythm Management Devices | Market Insights | Asia Pacific (Supplemental) | 2025
The Asia Pacific CRM device market will experience modest growth over the forecast period, driven primarily by the increasing volume of ICM procedures and the adoption of premium-priced devices,…
Report
Structural Heart Closure Devices – Market Insights – Asia Pacific
The Asia Pacific structural heart closure device market will grow strongly overall through 2034, supported by rising AF prevalence, increasing physician confidence in structural heart interventions…
Report
Biosurgical Agents – Market Insights – Asia Pacific
The biosurgical agent market in Asia Pacific will experience modest growth through 2034, driven by rising surgical procedure volumes and expanding use of biosurgical agents across a broader range…